Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2975854 | 0.81 | CNR2 (0.46) | CYP2A6ALDH1A1CYP1A2CNR2SMN1; SMN2 | |
| SCHEMBL7092910 | 0.81 | CYP2A6 (0.67) | CYP2A6ALDH1A1CYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL29890067 | 0.80 | CYP2A6 (0.56) | CYP2A6ALDH1A1CYP1A2CYP3A4NPY5R | |
| SCHEMBL28444314 | 0.80 | PTGS2 (0.62) | CYP2A6ALDH1A1CYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL27958635 | 0.80 | PTGS2 (0.62) | CYP2A6ALDH1A1CYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL16653633 | 0.79 | RPS6KA5 (0.50) | CYP2A6ALDH1A1CYP1A2CYP3A4NPY5R | |
| SCHEMBL30343535 | 0.79 | TRPV1 (0.46) | ALDH1A1CYP1A2CYP3A4CNR2SMN1; SMN2 | |
| SCHEMBL31223211 | 0.79 | CNR2 (0.45) | CYP2A6ALDH1A1CYP1A2CNR2SMN1; SMN2 | |
| SCHEMBL28235436 | 0.78 | PTGS2 (0.60) | CYP2A6ALDH1A1CYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL28440462 | 0.78 | PTGS2 (0.60) | CYP2A6ALDH1A1CYP1A2CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107674068-A | A kind of method for synthesizing Rynaxypyr derivatives intermediates | 浙江工业大学 | 2018-02-09 | — | — | CN | claimed |
| CN-115605467-B | PHD inhibitor compounds, compositions and uses thereof | 阿克比治疗有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120004851-A | PHD inhibitor compounds, compositions and uses thereof | 阿克比治疗有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-115605467-A | PHD inhibitor compounds, compositions and uses thereof | 阿克比治疗有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| CN-114456213-A | Organic electroluminescent material and device | 环球展览公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-107674068-A | A kind of method for synthesizing Rynaxypyr derivatives intermediates | 浙江工业大学 | 2018-02-09 | — | — | CN | disclosed |
| EP-2594554-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| WO-2012008435-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC2R, NR3C2, REN | CYP2A6 138/4885ALDH1A1 1151/4885CYP1A2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.